Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer

British Journal of Surgery

Volumn 101, Issue 6, 2014, Pages 595-604

  Jiang, L ^a   Yang, K H ^a   Chen, Y ^a   Guan, Q L ^a   Zhao, P ^a   Tian, J H ^a   Wang, Q ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; COMPARATIVE STUDY; HUMAN; LYMPH NODE DISSECTION; META ANALYSIS; METHODOLOGY; MIDDLE AGED; MORTALITY; OBSERVER VARIATION; PANCREAS; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOPERATION; REVIEW; SPLEEN; STATISTICS; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; LYMPH NODE EXCISION; MIDDLE AGED; OBSERVER VARIATION; PANCREAS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REOPERATION; SPLEEN; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898545249     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9497     Document Type: Review

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, et-al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol 2011; 17: 4421-4428.
3. Schmidt B, Yoon SS,. D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol 2013; 1073: 259-264.
4. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ,. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439-449.
5. Sasako M,. Principles of surgical treatment for curable gastric cancer. J Clin Oncol 2003; 21: 274s-275s.
6. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd English Edition. Gastric Cancer 1998; 1: 10-24.
7. Biffi R, Botteri E, Cenciarelli S, Luca F, Pozzi S, Valvo M, et-al. Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissection. Eur J Surg Oncol 2011; 37: 305-311.
8. Schwarz RE, Smith DD,. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 2007; 14: 317-328.
9. Kajitani T., The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 1981; 11: 127-139.
10. Tamura S, Takeno A, Miki H,. Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol 2011; 2011: 748745.
11. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et-al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004; 22: 2069-2077.
12. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et-al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.
13. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, et-al.; Italian Gastric Cancer Study Group. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004; 30: 303-308.
14. Roviello F, Marrelli D, Morgagni P, de Manzoni G, Di Leo A, Vindigni C, et-al.; Italian Research Group for Gastric Cancer. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. Ann Surg Oncol 2002; 9: 894-900.
15. Degiuli M, Sasako M, Ponti A,. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 2010; 97: 643-649.
16. Dent DM, Madden MV, Price SK,. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75: 110-112.
17. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et-al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-748.
18. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et-al.; Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
19. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et-al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347: 995-999.
20. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J,. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004; 91: 283-287.
21. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et-al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 309-315.
22. Bonenkamp JJ, van de Velde CJ, Sasako M, Hermans J,. R2 compared with R1 resection for gastric cancer: morbidity and mortality in a prospective, randomised trial. Eur J Surg 1992; 158: 413-418.
23. Robertson CS, Chung SC, Woods SD, Griffin SM, Raimes SA, Lau JT, et-al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994; 220: 176-182.
24. Edwards P, Blackshaw GR, Lewis WG, Barry JD, Allison MC, Jones DR,. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. Br J Cancer 2004; 90: 1888-1892.
25. Higgins JPT, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, Copenhagen; 2011.
26. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
27. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
28. Trikalinos TA, Balion CM, Coleman CI, Griffith L, Santaguida PL, Vandermeer B, et-al. Chapter 8: meta-analysis of test performance when there is a 'gold standard'. J Gen Intern Med 2012; 27 (Suppl 1): S56-S66.
29. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
30. Macaskill P, Walter SD, Irwig L,. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20: 641-654.
31. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF,. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
32. Li W-W, Chen L-K, Huang H, Tan J-M, Li M-Y,. Clinical study of D2 lymphadenectomy for gastric cancer. Chin J Cancer Prev Treat 2007; 14: 1891-1893.
33. Viudez-Berral A, Miranda-Murua C, Arias-de-la-Vega F, Hernández-García I, Artajona-Rosino A, Díaz-de-Liaño Á, et-al. Current management of gastric cancer. Rev Esp Enferm Dig 2012; 104: 134-141.